Summit Therapeutics (SMMT) Net Cash Flow (2017 - 2026)

Summit Therapeutics (SMMT) has reported Net Cash Flow for 10 consecutive years, with $312.8 million the latest figure, recorded in Q2 2026.

• Quarterly Net Cash Flow rose 262.57% year-over-year to $312.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $121.5 million (down 54.89% YoY) and the FY2025 annual result came in at $120.3 million, up 256.11% from the prior year.
• Net Cash Flow climbed to $312.8 million in Q2 2026 per SMMT's latest filing, from -$118.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for SMMT reached as high as $525.3 million in Q4 2022 and fell as low as -$578.1 million in Q1 2023.
• A 5-year average of $19.3 million and a median of -$2.0 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 6634.72% — and 2023, when it plunged 10024.15%.
• Year by year, Net Cash Flow stood at $525.3 million in 2022, then plunged by 90.98% to $47.4 million in 2023, then plunged by 76.36% to $11.2 million in 2024, then slumped by 218.55% to -$13.3 million in 2025, then surged by 2456.86% to $312.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $312.8 million, -$118.7 million, and -$13.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.